For advanced ALK+ lung cancer, European Society of Medical Oncology (ESMO) and NCCN guidelines recommend all three generations of ALK inhibitors such as alectinib, brigatinib and lorlatinib, noting significant improvement in PFS with second- and third-generation agents [63, 64]. The gene discussed is ALK; the disease is lung carcinoma.